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Abstract
We describe a patient with previously undiagnosed hypothyroidism who developed
rhabdomyolysis while taking a statin. He had no other precipitating factors. The statin was stopped,
intravenous fluids were started immediately and L-thyroxin was given after confirming the diagnosis
of hypothyroidism. His symptoms improved over a few days. Because rhabdomyolysis is a rare but
potentially life threatening disorder when complicated by acute tubular necrosis and renal failure,
physicians must pay special attention when starting statins in patients with hyperlipidemia.
Introduction
Statins (3-hydroxy-3-methylglutaryl coenzyme A reduct-
ase inhibitors) have been widely used as the first choice
for treatment of hyperlipidemia. Side effects of statins are
relatively infrequent [1]. The most common side effects
are skeletal muscle complaints, including clinically
important myositis and rhabdomyolysis, mild serum cre-
atine kinase (CK) elevations, myalgia with or without ele-
vated CK, muscle weakness, muscle cramps, and
persistent myalgia [2]. The risk of rhabdomyolysis and
other adverse effects with statin use can be exacerbated by
several factors, including compromised hepatic and renal
function, hypothyroidism, diabetes, and concomitant
medications [2]. Herein, we report a case of rhabdomyol-
ysis due to atorvastatin in a patient without any precipitat-
ing factors other than hypothyroidism.
Case presentation
A 56-year-old man was admitted to hospital with com-
plaints of a two week history of severe myalgia and proxi-
mal muscle weakness of the extremities, with difficulty in
exercise and climbing stairs. He denied vigorous physical
exercise and alcohol use. His medications consisted of
ramipril for hypertension and atorvastatin for hyperlipi-
demia which he had taken for the previous two weeks. He
had no familial or prior personal history of thyroid dis-
ease or muscle disorders. He had no previous history of
muscular toxicity with statin or fibrate use.
On physical examination, he was afebrile, had periorbital
puffiness, lip swelling and mild diffuse goitre, normal
heart rate (89 beats/min). All the limbs were swollen and
he had pitting edema. Other systems were normal.
On admission, laboratory measurements revealed: hemo-
globin 11.3 g/dl, total leucocyte count 7.7 × 109/l, serum
K 3,9 mEq/l, Na 137 mEq/l, urea 34 mg/dl, creatinine 1,4
mg/dl blood glucose 85 mg/dl. Serum muscle enzymes
were markedly elevated: CK 3471 IU/l (normal up to
170), CK-MB 90 IU/l (normal up to 15), LDH 730 IU/l
(150–500), Aspartate transaminase (AST) 91 IU/l, alanine
transaminase (ALT) 50 IU/l. Urine analysis showed mod-
erate blood on dipstick, but on microscopic examination
there were no erythrocytes. Therefore, we assumed that
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this was due to myoglobulinuria. Thyroid function tests
confirmed the diagnosis of hypothyroidism: thyroid stim-
ulating hormone (TSH) >75 uIU/ml (0.4–4), free T3
(FT3) 0.85 pg/ml (1.57–4.71), free T4 (FT4) 0.3 pg/dl
(0,85–1,78). The diagnosis was rhabdomyolysis second-
ary to the additive effect of hypothyroidism and atorvasta-
tin. Atorvastatin was stopped, intravenous fluids were
started immediately and L-thyroxin (100 μg/day) was
given after confirming the diagnosis of hypothyroidism.
His symptoms progressively improved in a few days. On
discharge, two week after admission, serum CK, AST and
ALT measurements had decreased to 668 IU/l, 23 IU/l,
and 27 IU/l respectively. TSH level was in the normal
range 6 weeks after starting treatment.
Discussion
The report describes a patient with rhabdomyolysis due to
the additive effect of undiagnosed hypothyroidism and
atorvastatin. Statins have been found to be effective in pri-
mary prevention as well as secondary prevention of coro-
nary disease [3]. Although statins are well tolerated by
most of the patients, they may cause myopathy, rhab-
domyolysis and elevated liver enzymes [4]. Medications
that inhibit cytochrome P-450 (CYP) 3A4, such as mac-
rolide antibiotics, antifungals, and cyclosporine, increase
serum concentrations of statins and the risk of rhabdomy-
olysis [2]. There have been several case reports of rhab-
domyolysis induced by hypothyroidism [5] but most of
the reported cases were precipitated by exercise [6]. In a
previous report, 11.7% of patients with primary hypothy-
roidism accidentally received statins without having the
diagnosis of hypothyroidism. Severity of hypothyroidism
might be partially associated with elevation of CK. Statins
might be a risk factor for severe myopathy and rhabdomy-
olysis in patients with hypothyroidism [1].
Conclusion
We wish to alert the physicians to the importance of early
recognition and treatment of hypothyroidism before start-
ing statins, which is essential in reducing risk of mortality
and complications from rhabdomyolysis. Screening thy-
roid function before starting statins is important to avoid
rare but serious complications.
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